SCHEMBL16665017

SCHEMBL16665017

CC(C)(C)[Si](OCc1cscn1)(c1ccccc1)c1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A3 Q01959 7/20 0.38
GABRA1 P14867 1/20 0.34
GABRG2 P18507 1/20 0.34
GABRB3 P28472 1/20 0.34
GABRA5 P31644 1/20 0.34
GABRA3 P34903 1/20 0.34
GABRA2 P47869 1/20 0.34
SLC6A2 P23975 2/20 0.34
SLC6A4 P31645 1/20 0.34
SLC16A3 O15427 1/20 0.34
SLC16A1 P53985 1/20 0.34
MCTS1 Q9ULC4 1/20 0.34
HTT P42858 2/20 0.33
ALDH1A1 P00352 1/20 0.33
HPGD P15428 1/20 0.33
MAPK1 P28482 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
GRM5 P41594 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3939800 0.77 SLC1A3 (0.36) SLC6A3GABRA1GABRG2GABRB3GABRA5
SCHEMBL1314001 0.75 AGXT (0.42) SLC6A2HTTALDH1A1MAPK1SMN1; SMN2
SCHEMBL8172914 0.75 MAPT (0.37) HTTALDH1A1MAPK1SMN1; SMN2NPC1
SCHEMBL531638 0.74 ALDH1A1 (0.38) SLC6A3HTTALDH1A1HPGDMAPK1
SCHEMBL5779483 0.73 BCHE (0.33) SLC6A3SMN1; SMN2NPC1RAB9APKM
SCHEMBL4151705 0.73 SMYD2 (0.33) HTTSMN1; SMN2GRM5CYP3A4SMYD2
SCHEMBL29623921 0.73 GABRA1 (0.38) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL3879562 0.73 SMYD2 (0.33) HTTSMN1; SMN2GRM5CYP3A4SMYD2
SCHEMBL8777276 0.73 KCNH2 (0.41) HTTSMN1; SMN2GRM5CYP3A4SMYD2
SCHEMBL2914346 0.72 SMYD2 (0.36) HTTSMN1; SMN2NPC1GRM5CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9278968-B2 Imidazopyridine compounds ASTELLAS PHARMA INC. (JP) 2016-03-08 US disclosed
US-20150232464-A1 IMIDAZOPYRIDINE COMPOUNDS ASTELLAS PHARMA INC. (JP) 2015-08-20 US disclosed
WO-2015057585-A1 THERAPEUTIC COMPOUNDS REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2015-04-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150232464-A1 IMIDAZOPYRIDINE COMPOUNDS PRKG1, PDE3B, PDE3A SLC6A3 4550/4885GABRA1 3205/4885GABRG2 2684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.